These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 34645283)

  • 41. Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study.
    Smith MN; Deloney L; Carter C; Weant KA; Eriksson EA
    J Thromb Thrombolysis; 2019 Aug; 48(2):250-255. PubMed ID: 30941571
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Andexanet alfa: A Novel Factor Xa Inhibitor Reversal Agent.
    Powell J; Taylor J; Garland SG
    Ann Pharmacother; 2019 Sep; 53(9):940-946. PubMed ID: 30813754
    [No Abstract]   [Full Text] [Related]  

  • 43. Andexanet alfa for reversal of factor Xa inhibitors: a critical review of the evidence.
    Abdulrehman J; Eikelboom JW; Siegal DM
    Future Cardiol; 2019 Nov; 15(6):395-404. PubMed ID: 31668083
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Four-factor prothrombin complex concentrate versus andexanet alfa for the reversal of traumatic brain injuries.
    Sadek E; Curtiss W; Andrews J; Hecht J
    Emerg Med J; 2024 Feb; 41(3):162-167. PubMed ID: 38267194
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Andexanet Alfa: First Global Approval.
    Heo YA
    Drugs; 2018 Jul; 78(10):1049-1055. PubMed ID: 29926311
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Andexanet Alfa: What We Have Learned from Clinical Trials and Real-World Data.
    Frol S; Oblak JP; Šabovič M; Kermer P
    CNS Drugs; 2024 Mar; 38(3):163-168. PubMed ID: 38396232
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of 4-Factor Prothrombin Complex Concentrates in Factor Xa Inhibitor-Associated Intracranial Bleeding.
    Korobey MJ; Sadaka F; Javed M; Moynihan M; Alsaei A
    Neurocrit Care; 2021 Feb; 34(1):112-120. PubMed ID: 32430804
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of oral factor Xa inhibitor-associated extracranial bleeding reversal with andexanet alfa.
    Nederpelt CJ; Naar L; Sylvester KW; Barra ME; Roberts RJ; Velmahos GC; Kaafarani HMA; Rosenthal MG; King DR
    J Thromb Haemost; 2020 Oct; 18(10):2532-2541. PubMed ID: 32738161
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tranexamic Acid for Intracerebral Hemorrhage in Patients on Non-Vitamin K Antagonist Oral Anticoagulants (TICH-NOAC): A Multicenter, Randomized, Placebo-Controlled, Phase 2 Trial.
    Polymeris AA; Karwacki GM; Siepen BM; Schaedelin S; Tsakiris DA; Stippich C; Guzman R; Nickel CH; Sprigg N; Kägi G; Vehoff J; Barinka F; Thilemann S; Maurer M; Wagner B; Traenka C; Gensicke H; De Marchis GM; Bonati LH; Fischer U; Z'Graggen WJ; Nedeltchev K; Wegener S; Baumgartner P; Engelter ST; Seiffge DJ; Peters N; Lyrer PA;
    Stroke; 2023 Sep; 54(9):2223-2234. PubMed ID: 37466000
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative analysis of andexanet alfa and prothrombin complex concentrate in reversing anticoagulation by rivaroxaban ex vivo.
    Rayatdoost F; Deventer K; Rossaint R; Schöchl H; Grottke O
    Br J Anaesth; 2024 Feb; 132(2):251-259. PubMed ID: 38030550
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Deterioration free discharge comparison of andexanet-alfa and prothrombin complex concentrates (PCC) for reversal of factor Xa inhibitor associated bleeds.
    Keinath JJ; Lekura J; Hauser CD; Bajwa MK; Bloome ME; Kalus JS; Jones MC
    J Thromb Thrombolysis; 2023 Aug; 56(2):315-322. PubMed ID: 37289371
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Apixaban and rivaroxaban anti-Xa level utilization for guidance of administration of andexanet alfa: a case series.
    Morton C; Lista A; Jakowenko N; Salazar E; Donahue KR
    J Thromb Thrombolysis; 2022 Jan; 53(1):235-239. PubMed ID: 34236614
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products.
    Castillo R; Chan A; Atallah S; Derry K; Baje M; Zimmermann LL; Martin R; Groysman L; Stern-Nezer S; Minokadeh A; Nova A; Huang W; Cang W; Schomer K
    J Thromb Thrombolysis; 2021 Jan; 51(1):151-158. PubMed ID: 32500220
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Real-world management of oral factor Xa inhibitor-related bleeds with reversal or replacement agents including andexanet alfa and four-factor prothrombin complex concentrate: a multicenter study.
    Coleman CI; Dobesh PP; Danese S; Ulloa J; Lovelace B
    Future Cardiol; 2021 Jan; 17(1):127-135. PubMed ID: 32618210
    [No Abstract]   [Full Text] [Related]  

  • 55. Andexanet alfa effectiveness and safety versus four-factor prothrombin complex concentrate (4F-PCC) in intracranial hemorrhage while on apixaban or rivaroxaban: A single-center, retrospective, matched cohort analysis.
    Parsels KA; Seabury RW; Zyck S; Miller CD; Krishnamurthy S; Darko W; Probst LA; Latorre JG; Cwikla GM; Feldman EA
    Am J Emerg Med; 2022 May; 55():16-19. PubMed ID: 35245776
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Andexanet alfa versus PCC products for factor Xa inhibitor bleeding: A systematic review with meta-analysis.
    White CM; Caroti KS; Bessada Y; Hernandez AV; Baker WL; Dobesh PP; van Haalen H; Rhodes K; Coleman CI
    Pharmacotherapy; 2024 May; 44(5):394-408. PubMed ID: 38721837
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Emergent external ventricular drain placement in patients with factor Xa inhibitor-associated intracerebral hemorrhage after reversal with andexanet alfa.
    Ammar AA; Elsamadicy AA; Ammar MA; Reeves BC; Koo AB; Falcone GJ; Hwang DY; Petersen N; Kim JA; Beekman R; Prust M; Magid-Bernstein J; Acosta JN; Herbert R; Sheth KN; Matouk CC; Gilmore EJ
    Clin Neurol Neurosurg; 2023 Mar; 226():107621. PubMed ID: 36791588
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Recommendations for the use of andexanet alfa in the management of bleeding in patients on oral factor Xa inhibitors in Switzerland: Guideline from the Working Party Hemostasis of the Swiss Society of Hematology.
    Angelillo-Scherrer A; Casini A; Studt JD; Gerber B; Alberio LA; Fontana P
    Swiss Med Wkly; 2023 Jul; 153():40113. PubMed ID: 37499160
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment of Factor-Xa Inhibitor-associated Bleeding with Andexanet Alfa or 4 Factor PCC: A Multicenter Feasibility Retrospective Study.
    Singer AJ; Concha M; Williams J; Brown CS; Fernandes R; Thode HC; Kirchman M; Rabinstein AA
    West J Emerg Med; 2023 Sep; 24(5):939-949. PubMed ID: 37788035
    [No Abstract]   [Full Text] [Related]  

  • 60. Andexanet alfa to reverse the anticoagulant activity of factor Xa inhibitors: a review of design, development and potential place in therapy.
    Sartori M; Cosmi B
    J Thromb Thrombolysis; 2018 Apr; 45(3):345-352. PubMed ID: 29372400
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.